Search research articles
Contact Us
Filters
Showing results (161-170 of 222) with videos related to
Page
of 23
Sort By:
The Lancet. Child & Adolescent Health
|
July 1, 2026
Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial
Maria Mazurkiewicz-Bełdzińska, Laurent Servais, Giovanni Baranello, et al.
Plos One
|
October 19, 2020
Medical management of muscle weakness in Duchenne muscular dystrophy
Sarah R Rivera, Sumit K Jhamb, Hoda Z Abdel-Hamid, et al.
The Lancet. Neurology
|
October 16, 2022
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial
Riccardo Masson, Maria Mazurkiewicz-Bełdzińska, Kristy Rose, et al.
The Journal of Clinical Investigation
|
May 9, 2024
Hepatocyte-intrinsic SMN deficiency drives metabolic dysfunction and liver steatosis in spinal muscular atrophy
Damien Meng-Kiat Leow, Yang Kai Ng, Loo Chien Wang, et al.
Muscle & Nerve
|
January 22, 2026
Liver Steatosis in Induced Hepatocytes From Carriers of Spinal Muscular Atrophy
Lingyu Sun, Damien Meng Kiat Leow, Loo Chien Wang, et al.
The New England Journal of Medicine
|
November 2, 2017
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Richard S Finkel, Eugenio Mercuri, Basil T Darras, et al.
Neurogenetics
|
February 29, 2012
Mutations in the satellite cell gene MEGF10 cause a recessive congenital myopathy with minicores
Steven E Boyden, Lane J Mahoney, Genri Kawahara, et al.
Neurology
|
March 24, 2019
X-linked myotubular myopathy: A prospective international natural history study
Mélanie Annoussamy, Charlotte Lilien, Teresa Gidaro, et al.
The New England Journal of Medicine
|
February 15, 2018
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Eugenio Mercuri, Basil T Darras, Claudia A Chiriboga, et al.
Plos One
|
February 22, 2017
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool
Danielle Ramsey, Mariacristina Scoto, Anna Mayhew, et al.
Page
of 23
Search research articles
Search
Showing results (161-170 of 222) with videos related to
Sort By:
Page
of 23
The Lancet. Child & Adolescent Health
|
July 1, 2026
Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial
Maria Mazurkiewicz-Bełdzińska, Laurent Servais, Giovanni Baranello, et al.
Plos One
|
October 19, 2020
Medical management of muscle weakness in Duchenne muscular dystrophy
Sarah R Rivera, Sumit K Jhamb, Hoda Z Abdel-Hamid, et al.
The Lancet. Neurology
|
October 16, 2022
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial
Riccardo Masson, Maria Mazurkiewicz-Bełdzińska, Kristy Rose, et al.
The Journal of Clinical Investigation
|
May 9, 2024
Hepatocyte-intrinsic SMN deficiency drives metabolic dysfunction and liver steatosis in spinal muscular atrophy
Damien Meng-Kiat Leow, Yang Kai Ng, Loo Chien Wang, et al.
Muscle & Nerve
|
January 22, 2026
Liver Steatosis in Induced Hepatocytes From Carriers of Spinal Muscular Atrophy
Lingyu Sun, Damien Meng Kiat Leow, Loo Chien Wang, et al.
The New England Journal of Medicine
|
November 2, 2017
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
Richard S Finkel, Eugenio Mercuri, Basil T Darras, et al.
Neurogenetics
|
February 29, 2012
Mutations in the satellite cell gene MEGF10 cause a recessive congenital myopathy with minicores
Steven E Boyden, Lane J Mahoney, Genri Kawahara, et al.
Neurology
|
March 24, 2019
X-linked myotubular myopathy: A prospective international natural history study
Mélanie Annoussamy, Charlotte Lilien, Teresa Gidaro, et al.
The New England Journal of Medicine
|
February 15, 2018
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Eugenio Mercuri, Basil T Darras, Claudia A Chiriboga, et al.
Plos One
|
February 22, 2017
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool
Danielle Ramsey, Mariacristina Scoto, Anna Mayhew, et al.
Page
of 23